White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression

被引:0
|
作者
Alexander Khalaf
Kathryn Edelman
Dana Tudorascu
Carmen Andreescu
Charles F Reynolds
Howard Aizenstein
机构
[1] Western Psychiatric Institute and Clinic,Department of Psychiatry
[2] University of Pittsburgh,undefined
来源
Neuropsychopharmacology | 2015年 / 40卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
White matter hyperintensities (WMHs) have been shown to be associated with the development of late-life depression (LLD) and eventual treatment outcomes. This study sought to investigate longitudinal WMH changes in patients with LLD during a 12-week antidepressant treatment course. Forty-seven depressed elderly patients were included in this analysis. All depressed subjects started pharmacological treatment for depression shortly after a baseline magnetic resonance imaging (MRI) scan. At 12 weeks, patients underwent a follow-up MRI scan, and were categorized as either treatment remitters (n=23) or non-remitters (n=24). Among all patients, there was as a significant increase in WMHs over 12 weeks (t(46)=2.36, P=0.02). When patients were stratified by remission status, non-remitters demonstrated a significant increase in WMHs (t(23)=2.17, P=0.04), but this was not observed in remitters (t(22)=1.09, P=0.29). Other markers of brain integrity were also investigated including whole brain gray matter volume, hippocampal volume, and fractional anisotropy. No significant differences were observed in any of these markers during treatment, including when patients were stratified based on remission status. These results add to existing literature showing the association between WMH accumulation and LLD treatment outcomes. Moreover, this is the first study to demonstrate similar findings over a short interval (ie 12 weeks), which corresponds to the typical length of an antidepressant trial. These findings serve to highlight the acute interplay of cerebrovascular ischemic disease and LLD.
引用
收藏
页码:3027 / 3035
页数:8
相关论文
共 50 条
  • [31] Optimizing the Treatment of Late-Life Depression
    Walaszek, Art
    AMERICAN JOURNAL OF PSYCHIATRY, 2024, 181 (01): : 7 - 10
  • [32] Advances in the treatment of late-life depression
    Mulsant, B. H.
    BIPOLAR DISORDERS, 2016, 18 : 51 - 51
  • [33] The diagnosis and treatment of late-life depression
    Rothschild, AJ
    JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 : 5 - 11
  • [34] Pharmacological treatment of late-life depression
    Ignjatovic, D
    Ignjatovic, M
    EUROPEAN PSYCHIATRY, 2004, 19 : 211S - 211S
  • [35] Treatment strategy for late-life depression
    Baba, Hajime
    PSYCHIATRY AND CLINICAL NEUROSCIENCES REPORTS, 2023, 2 (02):
  • [36] Mechanisms and treatment of late-life depression
    Alexopoulos, George S.
    TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)
  • [37] Pharmacological treatment of late-life depression
    Ignjatovic, D
    Ignjatovic, M
    Nutt, DJ
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 53 - 54
  • [38] Risk factors for falls during treatment for late-life depression
    Joo, J
    Lenze, E
    Mulsant, B
    Houck, P
    Begley, A
    Weber, L
    Pollock, B
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 10 (02): : 115 - 115
  • [39] Risk factors for falls during treatment of late-life depression
    Joo, JH
    Lenze, EJ
    Mulsant, BH
    Begley, AE
    Weber, EM
    Stack, JA
    Mazumdar, S
    Reynolds, CF
    Pollock, BG
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) : 936 - 941
  • [40] Symptoms of late-life depression - Frequency and change during treatment
    Nelson, JC
    Clary, CM
    Leon, AC
    Schneider, LS
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 13 (06): : 520 - 526